BMAL2 and neoplasm: Nonetheless, PC-PDX-3 and PC-PDX-4, characterized by ARNTL2 loss or low expression, demonstrated restricted effectiveness of erlotinib in inhibiting tumor growth (Fig. 7J-L and Fig. 7N-P).